Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,893 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study.
Tasaki Y, Hamamoto S, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Mimura Y, Sugiyama Y, Unno R, Okada A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: miyake m. Front Immunol. 2025 Jan 9;15:1483956. doi: 10.3389/fimmu.2024.1483956. eCollection 2024. Front Immunol. 2025. PMID: 39850887 Free PMC article.
Screening and prognostic roles of renal volumetry and scintigraphy in the assessment of living kidney transplant donors, considering the early recovery of the residual renal function.
Hori S, Tomizawa M, Inoue K, Yoneda T, Onishi K, Morizawa Y, Gotoh D, Nakai Y, Miyake M, Torimoto K, Tanaka N, Fujimoto K. Hori S, et al. Among authors: miyake m. BMC Nephrol. 2025 Jan 17;26(1):28. doi: 10.1186/s12882-024-03850-1. BMC Nephrol. 2025. PMID: 39825248 Free PMC article.
Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma.
Igaue S, Nozaki R, Utsunomiya D, Kubo Y, Kubo K, Kurita D, Yamamoto S, Miyake M, Ishiyama K, Oguma J, Kato K, Daiko H. Igaue S, et al. Among authors: miyake m. Dis Esophagus. 2025 Jan 7;38(1):doae114. doi: 10.1093/dote/doae114. Dis Esophagus. 2025. PMID: 39824221
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A. Daneshmand S, et al. Among authors: miyake m. Urol Oncol. 2025 Jan 15:S1078-1439(24)01044-5. doi: 10.1016/j.urolonc.2024.12.264. Online ahead of print. Urol Oncol. 2025. PMID: 39818460 Free article. Review.
1,893 results